Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes

Arthritis and Rheumatism

Volumn 48, Issue 7, 2003, Pages 2059-2066

  Metselaar, Josbert M ^a   Wauben, Marca H M ^b   Wagenaar Hilbers, Josee P A ^b   Boerman, Otto C ^c   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL INDIUM IN 111; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; GLUCOCORTICOID; LIPOSOME; MACROGOL; MACROGOL 2000; PHOSPHATIDYLETHANOLAMINE; PREDNISOLONE 21 PHOSPHATE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; EXPERIMENTAL MODEL; INFLAMMATORY DISEASE; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REMISSION; TISSUE DISTRIBUTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; PREDNISOLONE; RATS; RATS, INBRED LEW; REMISSION INDUCTION; TISSUE DISTRIBUTION;

EID: 0038002438     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11140     Document Type: Article

References (27)

1. Bodman KB, Roitt IM. The pathophysiology of rheumatoid arthritis. Fund Am Clin Immunol 1994;2:73-81.
2. Guidelines for the management of rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:713-22.
3. Saag KG. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:218-25.
4. Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis. Clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
5. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
6. Snell ES. The pharmacological properties of corticosteroids in relation to clinical efficacy. Br J Dermatol 1976;94 Suppl 12:15-23.
7. Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease. Budesonide: a model of targeted therapy. Alimen Pharmaco Ther 1997;11 Suppl 3:98-108.
8. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
9. Oku N, Namba Y. Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 1994;11:231-70.
10. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994;2:397-403.
11. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res 1994;54:987-92.
12. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001;91:1826-33.
13. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999;37:225-35.
14. Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, et al. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000;41:622-30.
15. Amselem S, Gabizon A, Barenholz Y. A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use. In: Gregoriadis G, editor. Liposome technology. Boca Raton, FL: CRC Press; 1993. p. 501-25.
16. Rouser G, Fkeischer S, Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970;5:494-6.
17. Koga T, Pearson CM. Immunogenicity and arthritogenicity in the rat of an antigen from Mycobacterium tuberculosis wax D. J Immunol 1973;111:599-608.
18. Derendorf H, Rohdewald P, Hochhaus G, Möllmann H. HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. J Pharm Biomed Anal 1986;4:197-206.
19. Weusten BLAM, Jacobs JWG, Bijlsma JWJ. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993;23:183-92.
20. Wollheim FA. Acute and long-term complications of corticosteroid pulse therapy. Scand J Rheumatol Suppl 1984;54:27-32.
21. Caldwell JR. Intra-articular corticosteroids: guide to selection and indications for use. Drugs 1996;52:507-14.
22. Hunter JA, Blyth TH. A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders. Drug Saf 1999;21:353-65.
23. Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 2000;293:996-1001.
24. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994;1190:99-107.
25. Carol M, Pelegri C, Castellote C, Franch A, Castell M. Immunohistochemical study of lymphoid tissues in adjuvant arthritis (AA) by image analysis: relationship with synovial lesions. Clin Exp Immunol 2000;120:200-8.
26. Storm G, Steerenberg PA, Emmen F, van Borssum Waalkes M, Crommelin DJ. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 1988;965:136-45.
27. Van Borssum Waalkes M, Scherphof GL. Liposome-incorporated 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine as a slow-release antitumor drug depot in rat liver macrophages. Sel Cancer Ther 1990;6:15-22.